From supporting the CF researchers of the future to funding research that can make a difference for everyone with CF, here we share just some of the ways we are making progress in achieving our goal of a life unlimited for everyone with cystic fibrosis.
Oli worked at Cystic Fibrosis Trust until 2020, becoming the first person with CF on the Senior Leadership Team. We know he touched many peoples’ lives over that time and would like to commemorate everything he achieved during his time at the Trust.
Content warning: this blog discusses loss and transplant.
We spoke to Abi about receiving a Helen Barrett Bright Ideas Award for her business 'Fairytales and Tiaras', and what it's like not being able to benefit from modulators.
Sheila is mum to Lorena, a talented artist with cystic fibrosis (CF) who died in January. Sheila tells us about Lorena’s life, how she wants people to remember her, and what she wishes more people understood about CF.
Content warning: This story touches on the topics of cancer, loss and grief, and mentions suicidal feelings.
Join Team CF at the incredible Colchester Zoo for the unique opportunity to run a chip timed 10k that starts in the heart of the Zoo, that’s right you will be starting between the Rhinos, Elephants, Giraffes and Zebras!
The UNIFED study is a study to understand how people respond to treatment for exacerbations during illness and recovery. We define exacerbations as when people with cystic fibrosis (CF) experience worsening of chest symptoms, like cough, breathlessness and wheezing. We will recruit people at risk of severe CF exacerbations when they are well and if/when they are subsequently admitted for treatment of an exacerbation. We will track symptoms and lung function during recovery, and collect blood, sputum and stool samples to allow us to explore the different things that occur in the body during an exacerbation and how/if they relate...
Trials Tracker ID
TT014805
Age range
16 years and older
Length of participation
Maximum of monitoring over 2 years. Participants that present with an exacerbation will be monitored during stay in hospital, up to a maximum of 17 days, and at follow-up 6-14 weeks later. After this follow-up visit there will be no further participation
